{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:51:55Z","timestamp":1791273115555,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["50074"],"award-info":[{"award-number":["50074"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer of Unknown Primary (CUP) is an aggressive malignancy with poor patient outcomes. For most patients, the primary site remains elusive, limiting therapeutic options to non-specific chemotherapy. The CUP-COMP study (NCT04750109) assessed the feasibility of integrating molecular profiling with a National Molecular Tumour Board (MTB) into the treatment pathway of patients with CUP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with histologically confirmed CUP were recruited from seven UK sites. Blood- and\/or tissue-based molecular profiling was performed with results interpreted via an MTB identifying potentially actionable alterations (PAA). Retrospective tissue and blood alteration analysis assessed concordance and utility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>113\/117 patients recruited between June 2021 and February 2023 completed 12 months of follow-up. Of 115 patients with successful molecular profiling, blood-based profiling was more successful (93%) than tissue-based (61%). The MTB identified PAAs in 63% (73\/115), with 26% (31\/117) treated using a precision medicine (PM)\u00a0approach. Primary tumours were subsequently confirmed\/suspected in 41 patients. Median overall survival (OS) was 9.5 months. Detecting a PAA in blood was impacted by tumour fraction (33% of patients had a tumour fraction &lt;1%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>CUP-COMP demonstrates liquid biopsies are highly feasible in CUP. While tissue profiling remains preferable, blood-based profiling offers a timely viable alternative to tissue, especially in selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03519-6","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:49:29Z","timestamp":1784555369000},"page":"1255-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective national precision medicine trial evaluating the feasibility of blood-based molecular profiling in patients with Cancer of Unknown Primary (CUP-COMP)"],"prefix":"10.1038","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-8206","authenticated-orcid":false,"given":"Alicia-Marie","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-7121","authenticated-orcid":false,"given":"Matthew","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8777-4786","authenticated-orcid":false,"given":"Matthew","family":"Concannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-0364","authenticated-orcid":false,"given":"Sally","family":"Clive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Keen","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Medley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliyaz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoulikha","family":"Zair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Gillham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-Anne","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5943-8440","authenticated-orcid":false,"given":"Mark","family":"Stares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oliviera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Burghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1082","authenticated-orcid":false,"given":"Natalie","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3519_CR1","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1002\/cam4.1689","volume":"7","author":"C Binder","year":"2018","unstructured":"Binder C, Matthes KL, Korol D, Rohrmann S, Moch H. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med. 2018;7:4814\u201324.","journal-title":"Cancer Med"},{"key":"3519_CR2","unstructured":"CRUK Cancer Research UK. Cancer of Unknown Primary Cancer Statistics [Internet]. Updated 2020 [Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/cancer-of-unknown-primary."},{"key":"3519_CR3","doi-asserted-by":"crossref","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Baciarello G, Delorme S, Hemminki K, et al. Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;34:228\u201346.","DOI":"10.1016\/j.annonc.2022.11.013"},{"key":"3519_CR4","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","volume":"404","author":"A Kr\u00e4mer","year":"2024","unstructured":"Kr\u00e4mer A, Bochtler T, Pauli C, Shiu K-K, Cook N, de Menezes JJ, et al. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study. Lancet. 2024;404:527\u201339.","journal-title":"Lancet"},{"key":"3519_CR5","doi-asserted-by":"crossref","unstructured":"Posner A, Prall OW, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A, et al. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. J Pathol. 2022;259:81\u201392.","DOI":"10.1002\/path.6022"},{"key":"3519_CR6","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","volume":"25","author":"X Liu","year":"2024","unstructured":"Liu X, Zhang X, Jiang S, Mo M, Wang Q, Wang Y, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024;25:1092\u2013102.","journal-title":"Lancet Oncol"},{"key":"3519_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.seminoncol.2008.10.006","volume":"36","author":"JD Hainsworth","year":"2009","unstructured":"Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol. 2009;36:44\u201351.","journal-title":"Semin Oncol"},{"key":"3519_CR8","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v133\u2013v8.","journal-title":"Ann Oncol"},{"key":"3519_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.gim.2022.01.001","volume":"24","author":"P Horak","year":"2022","unstructured":"Horak P, Griffith M, Danos AM, Pitel BA, Madhavan S, Liu X, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022;24:986\u201398.","journal-title":"Genet Med"},{"key":"3519_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/jmedgenet-2019-106759","volume":"57","author":"A Garrett","year":"2020","unstructured":"Garrett A, Callaway A, Durkie M, Cubuk C, Alikian M, Burghel GJ, et al. Cancer variant interpretation group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network. J Med Genet. 2020;57:829\u201334.","journal-title":"J Med Genet"},{"key":"3519_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and Guidelines for the Interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American pathologists. J Mol Diagn. 2017;19:4\u201323.","journal-title":"J Mol Diagn"},{"key":"3519_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"3519_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","volume":"34","author":"Z Kuzbari","year":"2023","unstructured":"Kuzbari Z, Bandlamudi C, Loveday C, Garrett A, Mehine M, George A, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34:215\u201327.","journal-title":"Ann Oncol"},{"key":"3519_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6988","volume":"13","author":"S Harvey","year":"2024","unstructured":"Harvey S, Stares M, Scott JA, Thottiyil TJV, Conway AM, Haigh R, et al. Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary. Cancer Med. 2024;13:e6988.","journal-title":"Cancer Med"},{"key":"3519_CR15","doi-asserted-by":"publisher","first-page":"12440","DOI":"10.18632\/oncotarget.2574","volume":"5","author":"Z Gatalica","year":"2014","unstructured":"Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget. 2014;5:12440\u20137.","journal-title":"Oncotarget"},{"key":"3519_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2018.02.021","volume":"94","author":"Z Gatalica","year":"2018","unstructured":"Gatalica Z, Xiu J, Swensen J, Vranic S. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer. 2018;94:179\u201386.","journal-title":"Eur J Cancer"},{"key":"3519_CR17","doi-asserted-by":"publisher","first-page":"44322","DOI":"10.18632\/oncotarget.10035","volume":"7","author":"H L\u00f6ffler","year":"2016","unstructured":"L\u00f6ffler H, Pfarr N, Kriegsmann M, Endris V, Hielscher T, Lohneis P, et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget. 2016;7:44322\u20139.","journal-title":"Oncotarget"},{"key":"3519_CR18","doi-asserted-by":"crossref","unstructured":"Varghese AM, Arora A, Capanu M, Camacho N, Won HH, Zehir A, et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol. 2017;28:3015\u201321.","DOI":"10.1093\/annonc\/mdx545"},{"key":"3519_CR19","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1158\/0008-5472.CAN-17-0628","volume":"77","author":"S Kato","year":"2017","unstructured":"Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, et al. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res. 2017;77:4238\u201346.","journal-title":"Cancer Res"},{"key":"3519_CR20","doi-asserted-by":"publisher","first-page":"8225","DOI":"10.1007\/s00432-023-04741-y","volume":"149","author":"L Weiss","year":"2023","unstructured":"Weiss L, Heinrich K, Zhang D, Dorman K, R\u00fchlmann K, Hasselmann K, et al. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective. J Cancer Res Clin Oncol. 2023;149:8225\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3519_CR21","doi-asserted-by":"publisher","first-page":"e13666","DOI":"10.1200\/JCO.2023.41.16_suppl.e13666","volume":"41","author":"N Jacquin","year":"2023","unstructured":"Jacquin N, Kamal M, Bieche I, Dupain C, Guillou I, Rouleau E, et al. Effect of national multidisciplinary tumor boards on diagnostic stratification and therapeutic management in cancers of unknown primary. J Clin Oncol. 2023;41:e13666\u2013e.","journal-title":"J Clin Oncol"},{"key":"3519_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41416-023-02254-6","volume":"129","author":"A van Mourik","year":"2023","unstructured":"van Mourik A, Tonkin-Hill G, O\u2019Farrell J, Waller S, Tan L, Tothill RW, et al. Six-year experience of Australia\u2019s first dedicated cancer of unknown primary clinic. Br J Cancer. 2023;129:301\u20138.","journal-title":"Br J Cancer"},{"key":"3519_CR23","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1016\/j.annonc.2024.08.2205","volume":"35","author":"T Bochtler","year":"2024","unstructured":"Bochtler T, Kramer A, Pauli C, Dur\u00e1n-Pacheco G, Arslan C, Bigot F, et al. Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study. Ann Oncol. 2024;35:S238\u2013S308.","journal-title":"Ann Oncol"},{"key":"3519_CR24","doi-asserted-by":"crossref","unstructured":"Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, et al. Feasibility and value of genomic-profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023;115:994\u201397.","DOI":"10.1093\/jnci\/djad095"},{"key":"3519_CR25","doi-asserted-by":"crossref","unstructured":"Conway AM, Morris GC, Smith S, Manoharan P, Mitchell C, Backen A, et al. editors. Intrahepatic cholangiocarcinoma (iCCA) hidden amongst the unknown: a retrospective analysis of cancer of unknown primary (CUP) cases from a tertiary cancer centre. Ann Oncol. 2021;32:S380\u20131.","DOI":"10.1016\/j.annonc.2021.08.337"},{"key":"3519_CR26","doi-asserted-by":"publisher","first-page":"e769","DOI":"10.1002\/onco.13744","volume":"26","author":"C Pauli","year":"2021","unstructured":"Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross JS, et al. A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO Guidelines: the CUPISCO trial experience. Oncologist. 2021;26:e769\u2013e79.","journal-title":"Oncologist"},{"key":"3519_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113540","volume":"200","author":"G Zaun","year":"2024","unstructured":"Zaun G, Borchert S, Metzenmacher M, Lueong S, Wiesweg M, Zaun Y, et al. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies. Eur J Cancer. 2024;200:113540.","journal-title":"Eur J Cancer"},{"key":"3519_CR28","doi-asserted-by":"crossref","unstructured":"Benvenuti S, Milan M, Geuna E, Pisacane A, Senetta R, Gambardella G, et al. Cancer of unknown primary: genetic evidence for a novel nosological entity? A case report. EMBO Mol Med. 2020;12:EMMM201911756.","DOI":"10.15252\/emmm.201911756"},{"key":"3519_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102035","volume":"8","author":"CB Westphalen","year":"2023","unstructured":"Westphalen CB, Federer-Gsponer J, Pauli C, Karapetyan AR, Chalabi N, Dur\u00e1n-Pacheco G, et al. Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study. ESMO Open. 2023;8:102035.","journal-title":"ESMO Open"},{"key":"3519_CR30","doi-asserted-by":"crossref","unstructured":"Rothwell DG, Ayub M, Cook N, Thistlethwaite F, Carter L, Dean E, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25:738\u201343.","DOI":"10.1038\/s41591-019-0380-z"},{"key":"3519_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.annonc.2021.11.004","volume":"33","author":"G Middleton","year":"2022","unstructured":"Middleton G, Robbins H, Andre F, Swanton C. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. Ann Oncol. 2022;33:143\u201357.","journal-title":"Ann Oncol"},{"key":"3519_CR32","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24\u2013ra24.","journal-title":"Sci Transl Med"},{"key":"3519_CR33","doi-asserted-by":"publisher","first-page":"r1130","DOI":"10.1136\/bmj.r1130","volume":"389","author":"J Wise","year":"2025","unstructured":"Wise J. Liquid biopsy for lung and breast cancers becomes available across the NHS in England. BMJ. 2025;389:r1130.","journal-title":"BMJ"},{"key":"3519_CR34","doi-asserted-by":"publisher","first-page":"e394","DOI":"10.1002\/onco.13597","volume":"26","author":"JS Ross","year":"2021","unstructured":"Ross JS, Sokol ES, Moch H, Mileshkin L, Baciarello G, Losa F, et al. Comprehensive genomic profiling of carcinoma of unknown primary origin: retrospective molecular classification considering the CUPISCO study design. Oncologist. 2021;26:e394\u2013402.","journal-title":"Oncologist"},{"key":"3519_CR35","doi-asserted-by":"crossref","unstructured":"Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, et al. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021;13:96.","DOI":"10.1186\/s13073-021-00898-8"},{"key":"3519_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726\u201336.","journal-title":"N Engl J Med"},{"key":"3519_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"3519_CR38","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","volume":"36","author":"M Javle","year":"2018","unstructured":"Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276\u201382.","journal-title":"J Clin Oncol"},{"key":"3519_CR39","volume":"15","author":"JK Jallah","year":"2023","unstructured":"Jallah JK, Dweh TJ, Anjankar A, Palma O. A review of the advancements in targeted therapies for breast cancer. Cureus. 2023;15:e47847.","journal-title":"Cureus"},{"key":"3519_CR40","doi-asserted-by":"crossref","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017;1:1\u201316.","DOI":"10.1200\/PO.17.00011"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03519-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:01:44Z","timestamp":1791270104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03519-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["3519"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03519-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NC has received: 1. research grants from Roche Products Limited, 2. consulting fees from Roche Products Limited and REDX Pharmaceuticals, 3. payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche Products Limited Pharmaceuticals, 4. support for attending meetings and\/or travel from Roche Pharmaceuticals, 5. research funding to research team from AstraZeneca, Orion, Roche Products Limited, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, RedX Pharmaceuticals, Stemline Therapeutics, LOXO-oncology, Avacta, Boehringer Ingelheim, Merck and Tarveda Therapeutics, 6. been the named investigator at the patent registered by \u201cCancer Research Technology Ltd,\u201d 7. participated in data safety monitoring board or advisory board at Roche Products Limited and Cancer Research UK, 8. had the leadership or fiduciary role in CUP Foundation. KK has received 1. payment or honoraria for lectures, presentations, speaker\u2019s bureaus, manuscript writing, or educational events from Roche Products Limited, 2. support for attending meetings and\/or travel from Roche Products Limited. AMC has received 1. support for attending meetings and\/or travel from Roche Products Limited and 2. been the named investigator at the patent registered by \u201cCancer Research Technology Ltd,\u201d. KW is employed by Roche Products Limited (UK) and receive shares in Roche None of the other authors have declared any disclosures related to this manuscript.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Ethical approval was obtained from the Yorkshire and The Humber\u2013Sheffield Research Ethics Committee (REC: 20\/YH\/0305) and trial sponsorship was undertaken by The Christie NHS Foundation Trust. All patients provided fully informed written consent for the trial.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}